Consult Rounds Tweetorial: 1) A 60 y old female- no PMH- arrives for Fever of Unknown origin- COVID test X3 neg, no source found- blood clx, urine clx, all neg scans. - Rheum workup neg. Renal function crt 0.9-1.2mg/dl and urinalysis bland with no WBC and no RBCS, or casts
2) Infectious disease says- less likely culprit is infection- get a Tagged WBC scan.. WBC scan lights up only in the kidneys bilaterally... Renal consult called!!
3)What is your ddx for a positive WBC scan in the kidneys?
4) Would you do a kidney biopsy?
5) On further history- hydralazine was started 1 month prior for new worsening HTN.. Most of the symptoms corelate with starting of the drug- including fevers. ANCA titers, ANA, dsDNA, anti histone negative, ongoing fevers but normal crt, urinalysis with no hematuria or protein.
6) Kidney biopsy done after holding hydralazine: what do you think it will show?
7) The kidney biopsy confirmed early AIN- likely drug induced and chronic IgA nephropathy... go figure!!
8) Imaging modalities to diagnose AIN:
Gallium scan has been employed in the evaluation of AIN for the past 3 decades. Kidneys with AIN enhance as a result up the binding of gallium to lactoferrin, which is produced and released by leukocytes within the interstitium.
9)In addition, lactoferrin is found on the surface of invading inflammatory cells, primarily lymphocytes, and also binds gallium. Thus, gallium would be expected to enhance kidneys with AIN. pubmed.ncbi.nlm.nih.gov/20348147/
10) what about PET-scan? A single publication noted a positive 2-[18F] fluoro-2-deoxy-D glucose-positron emission tomography (FDG-PET) scan in 2 patients with severe AKI due to biopsy-proven AIN
11)Uptake of tracer in the setting of AIN is based on the premise that FDG accumulates not only in tumor cells but also in the lymphocytes, macrophages, neutrophils and fibroblasts of inflammatory lesions -- this needs further study!!! academic.oup.com/ckj/article/3/…
12) But WBC (combined Indium-111) scan??? Here is a breakdown of various nuclear medicine scans: ncbi.nlm.nih.gov/pmc/articles/P…
13) A rat study showed that Indium scans cannot help in AIN. jnm.snmjournals.org/content/54/sup… This study was conducted to determine if 111In-labeled leukocyte imaging (InWBC) could be used to differentiate AIN from ATN..
14) Oh well,.. AIN is a tough diagnosis to have and who knows if there will ever be an imaging to diagnose it...
end tweetorial! @threadreaderapp#unroll
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1) New study Tweetorial: Identifying patients with CKD risk at the time of nephrectomy: When to initiate nephrology consult in collaboration with @purvasharma821@VBijol and Urology team with lead by Yihe Yang @JOncoNeph VA by @edgarvlermamd
2)The prevalence of CKD is high among kidney neoplasm patients because of the overlapping risk factors. Our purpose was to identify kidney cancer survivors with higher CKD risk.
Short Tweetorial from my talk on Membranous Nephropathy: 2021 Update: #glomerular disease 1. Three types of Membranous- Primary, Secondary and Allo-immune
2. Causes of secondary MN: Cancers, Drugs, Infections and autoimmune disease( like any other disease).
What about Scrt... SGLT2i therapy can cause an acute drop in eGFR. In the absence of hemodynamic instability or an alternate cause of AKI, the initial decline in GFR by 4-8 ml/min/1.73m2 after SGLT2i initiation is likely due to reduction in intra-glomerular pressure.
A typical patient included in CREDENCE would lose 4.6 ml/min/year of eGFR if treated with RAASi only, reaching ESKD in 10 years. However, if canagliflozin is added to his treatment, he would only lose 1.85 ml/min/year of eGFR, delaying ESKD by 15 kidney360.asnjournals.org/content/early/…
SGLT2 is responsible for reabsorbing up to 90% (animal data) of the glucose filtered at the glomerulus. The remaining 10% (animal data) is reabsorbed by SGLT1 that is expressed on the luminal (brush border) surface of cells of the S3 segment of the proximal tubule
Pathophysiology of Diabetic Nephropathy and role of SGLT2
2. Most data regarding outcomes of kidney transplantation in patients with myeloma come from single center case series. With the advent of novel treatment choices, it remains unclear if outcomes of kidney transplant recipients with myeloma have improved in last decade
3.Literature reviews for multiple myeloma or smoldering MM with kidney transplantation were performed. Case series with at least one kidney transplant recipient with a history of multiple myeloma were included.